Advertisement

The Changing Face of HIV

  • Marshall J. GlesbyEmail author
  • Merle Myerson
Chapter

Abstract

The face of HIV has changed drastically since the unusual infections were initially reported in young, gay men in the early 1980s. Key to this was the identification of the human immunodeficiency virus and development and evolution of antiretroviral therapy.

As a result, death from HIV was no longer inevitable, and patients are now often able to live productive and disease-free lives. Many are living full lives and to ages similar to the general population.

However, now in the age of viral suppression, there are new problems that impact on the health and quality of life of patients infected with HIV. Diseases of aging have become the leading causes of morbidity and mortality in this patient population. Cardiovascular disease and cancer are becoming more common in these patients. It is important for the clinician to become familiar with diagnosis and management of cardiovascular disease and perhaps even more important—recognizing and treating risk factors that result in manifest cardiovascular disease.

Keywords

Epidemiology Antiretroviral therapy Cardiovascular disease HIV 

References

  1. 1.
    Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250–2.Google Scholar
  2. 2.
    Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425–31.CrossRefGoogle Scholar
  3. 3.
    Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, et al. An outbreak of community-acquired pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–8.CrossRefGoogle Scholar
  4. 4.
    Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305(24):1439–44.CrossRefGoogle Scholar
  5. 5.
    Sepkowitz KA. AIDS—the first 20 years. N Engl J Med. 2001;344(23):1764–72.CrossRefGoogle Scholar
  6. 6.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefGoogle Scholar
  7. 7.
    Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRefGoogle Scholar
  8. 8.
    Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr, Klein DB, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39–46.CrossRefGoogle Scholar
  9. 9.
    Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem A, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–8.CrossRefGoogle Scholar
  10. 10.
    Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS. 2010;24(10):1537–48.PubMedGoogle Scholar
  11. 11.
    Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12.CrossRefGoogle Scholar
  12. 12.
    Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–22.CrossRefGoogle Scholar
  13. 13.
    Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118(2):198–210.CrossRefGoogle Scholar
  14. 14.
    Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.CrossRefGoogle Scholar
  15. 15.
    El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.CrossRefGoogle Scholar
  16. 16.
    Magkos F, Mantzoros CS. Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metab Clin Exp. 2011;60(6):749–53.CrossRefGoogle Scholar
  17. 17.
    Kaplan-Lewis E, Aberg JA, Lee M. Atherosclerotic cardiovascular disease and anti-retroviral therapy. Curr HIV/AIDS Rep. 2016;13(5):297–308.CrossRefGoogle Scholar
  18. 18.
    Myerson M, Poltavskiy E, Armstrong EJ, Kim S, Sharp V, Bang H. Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients. J Acquir Immune Defic Syndr. 2014;66(4):370–7.CrossRefGoogle Scholar
  19. 19.
    Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Phys AIDS Care (Chicago, Ill: 2002). 2012;11(1):20–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of MedicineWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Division of Cardiology, Bassett Medical CenterBassett Research Institute, Center for Clinical ResearchCooperstownUSA

Personalised recommendations